title: Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity.
abstract: OBJECTIVE
  We sought to review efficacy and toxicity of an 8-day methotrexate (MTX) regimen in the treatment of patients with low-risk gestational trophoblastic neoplasia (GTN) from the French Trophoblastic Disease Reference Center.
  
  
  METHODS
  Between 1999 and 2006, 142 low-risk GTNs were diagnosed according to International Federation of Gynecology and Obstetrics (FIGO) criteria for GTN and to the FIGO scoring system. We report their characteristics, remission/resistance/recurrence rates, and treatment toxicity.
  
  
  RESULTS
  The 8-day MTX regimen achieved a 77.5% remission rate. All patients but 1 (99.9%) achieved remission and remained disease free until the time of analysis. Severe (grade 3 or 4) blood/bone marrow toxicity and metabolic/laboratory toxicity was noted in 4.2% of cases, of which 2 (1.4%) were grade 4.
  
  
  CONCLUSIONS
  For patients with GTN diagnosed according to FIGO criteria and considered low risk according to the FIGO scoring system, an 8-day MTX regimen is an adequate treatment associating a high rate of remission to a low rate of toxicity.
authors.affiliation: Université de Lyon, F-69622, Lyon, France.
authors.forename: Gihad Elias
authors.initials: GE
authors.lastname: Chalouhi
authors.forename: François
authors.initials: F
authors.lastname: Golfier
authors.forename: Pauline
authors.initials: P
authors.lastname: Soignon
authors.forename: Jerome
authors.initials: J
authors.lastname: Massardier
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Guastalla
authors.forename: Veronique
authors.initials: V
authors.lastname: Trillet-Lenoir
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Schott
authors.forename: Daniel
authors.initials: D
authors.lastname: Raudrant
mesh_terms: D000293:Adolescent; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D031901:Gestational Trophoblastic Disease / Q000145:classification / Q000188:drug therapy*; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use* / Q000633:toxicity; D008875:Middle Aged; D011247:Pregnancy; D012307:Risk Factors; D055815:Young Adult
chemical_list: D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate